Format

Send to

Choose Destination
J Clin Psychiatry. 1988 Aug;49 Suppl:40-5.

Pharmacology of sertraline: a review.

Author information

1
Department of Neuroscience, Pfizer Inc., Groton, CT 06340.

Abstract

Sertraline is a member of a new class of psychotherapeutic agents that selectively inhibit serotonin reuptake in the brain. Animal studies have demonstrated that inhibition of serotonin reuptake leads to enhanced serotonergic neurotransmission and indirectly results in a down-regulation of beta-adrenoceptors. The preclinical pharmacology of sertraline predicts antidepressant activity without accompanying anticholinergic, cardiotonic, or sedative side effects. Recent laboratory and clinical observations pertaining to body weight and obsessive compulsive disorder suggest the possibility of broader clinical indications for selective serotonin reuptake blockers such as sertraline.

PMID:
3045112
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center